Estimating the cost impact of atrial fibrillation using a prospective cohort study and population-based controls
Open Access
Abstract
Aims Atrial fibrillation (AF) costs are expected to be substantial, but cost comparisons with the general population are scarce. Using data from the prospective Swiss-AF cohort study and population-based controls, we estimated the impact of AF on direct healthcare costs from the Swiss statutory health insurance perspective. Methods Swiss-AF patients, enrolled from 2014 to 2017, had documented, prevalent AF. We analysed 5 years of follow-up, where clinical data, and health insurance claims in 42% of the patients were collected on a yearly basis. Controls from a health insurance claims database were matched for demographics and region. The cost impact of AF was estimated using five different methods: (1) ordinary least square regression (OLS), (2) OLS-based two-part modelling, (3) generalised linear model-based two-part modelling, (4) 1:1 nearest neighbour propensity score matching and (5) a cost adjudication algorithm using Swiss-AF data non-comparatively and considering clinical data. Cost of illness at the Swiss national level was modelled using obtained cost estimates, prevalence from the Global Burden of Disease Project, and Swiss population data. Results The 1024 Swiss-AF patients with available claims data were compared with 16 556 controls without known AF. AF patients accrued CHF5600 (EUR5091) of AF-related direct healthcare costs per year, in addition to non-AF-related healthcare costs of CHF11100 (EUR10 091) per year accrued by AF patients and controls. All five methods yielded comparable results. AF-related costs at the national level were estimated to amount to 1% of Swiss healthcare expenditure. Conclusions We robustly found direct medical costs of AF patients were 50% higher than those of population-based controls. Such information on the incremental cost burden of AF may support healthcare capacity planning.Keywords
Funding Information
- Swiss National Science Foundation (105318_189195 / 1)
- Swiss National Science Foundation (32003B_197524)
- Swiss National Science Foundation (32473B_176178)
- Swiss National Science Foundation (33CS30_148474)
- Swiss National Science Foundation (33CS30_177520)
- Foundation for Cardiovascular Research (N/A)
- University of Basel (N/A)
- Schweizerische Herzstiftung (N/A)
This publication has 23 references indexed in Scilit:
- Contemporary Trends of Hospitalization for Atrial Fibrillation in the United States, 2000 Through 2010Circulation, 2014
- Identifying patients with chronic conditions using pharmacy data in Switzerland: an updated mapping approach to the classification of medicationsBMC Public Health, 2013
- Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st centuryInternational Journal of Cardiology, 2013
- Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United StatesCirculation: Cardiovascular Quality and Outcomes, 2011
- Cost of Illness and Drivers of Cost in Atrial Fibrillation in Sweden and GermanyApplied Health Economics and Health Policy, 2010
- Atrial fibrillation: the cost of illness in SwedenThe European Journal of Health Economics, 2010
- The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in GermanyValue in Health, 2009
- Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillationEP Europace, 2008
- Assessing the Direct Costs of Treating Nonvalvular Atrial Fibrillation in the United StatesValue in Health, 2006
- Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UKHeart, 2004